Related Experiment Videos
CHART for non-small-cell lung cancer--promises and limitations
1Department of Medicine, University of Chicago Medical Center, IL 60637-1470, USA.
Lancet (London, England)
|July 19, 1997
Summary
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer.
Annals of oncology : official journal of the European Society for Medical Oncology·2023
OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology·2018
Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases.
Annals of oncology : official journal of the European Society for Medical Oncology·2018
Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer.
Annals of oncology : official journal of the European Society for Medical Oncology·2016
Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling.
Clinical and translational science·2016
Pathways to improving combined modality therapy for stage III nonsmall-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology·2015